Description: Dapatorq V100 contains Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2 and Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor.
Pharmaceutical Dosage Form: Tablet
Route of Administration: Oral
Composition: Each uncoated bilayered tablet contains:
Dapagliflozin Propanediol Monohydrate USP
Eq. to Dapagliflozin 10 mg
Vildagliptin IP 100 mg
(As sustained release)
Excipients q.s.
Mechanism of Action: Dapagliflozin inhibits SGLT2 thus reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin improves both fasting and post-prandial plasma glucose levels. Vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
Indications: Dapatorq V100 is indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.
Dosage: As directed by the physician.
Storage: Store protected from light & moisture, at a temperature not exceeding 25°C.
Presentation: 10 x 10
Side effects: The following adverse reactions may occur:
Genital Infections
Urinary Tract Infection
Hypoglycaemia
Dizziness
Rash
Back Pain
Dysuria
Polyuria
Dyslipidaemia
Contraindications:
Dapatorq V100 is contraindicated in patients with known hypersensitivity to Dapagliflozin, Vildaglitin or any of the components of this product.
Drug Interactions:
Diuretics
Rifampicin
Mefenamic Acid
Warfarin
Digoxin
ACE-inhibitors
